Drug Patents owned by Jdp

1. List of Quzyttir drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9180090 JDP Non-sedating antihistamine injection formulations and methods of use thereof
Feb, 2030

(7 years from now)

US8513259 JDP Non-sedating antihistamine injection formulations and methods of use thereof
Feb, 2030

(7 years from now)

US9119771 JDP Non-sedating antihistamine injection formulations and methods of use thereof
Feb, 2030

(7 years from now)

US8314083 JDP Non-sedating antihistamine injection formulations and methods of use thereof
Feb, 2030

(7 years from now)

US8263581 JDP Non-sedating antihistamine injection formulations and methods of use thereof
Feb, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Oct 4, 2022

Drugs and Companies using CETIRIZINE HYDROCHLORIDE ingredient

Market Authorisation Date: 04 October, 2019

Treatment: Treatment of acute urticaria; Method of increasing peak plasma or onset of plasma concentration by intravenous injection in individuals in need of treatment for acute urticaria; Method of treatment in patients with concomitant angioedema

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in